Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Breast 1

Conditions

Breast Neoplasms 66Lymphoma 35Neutropenia 30Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Non-Hodgkin 18Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Hodgkin Disease 13Sarcoma 11Multiple Myeloma 11Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Rhabdomyosarcoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Chemotherapy-induced Neutropenia 7Central Nervous System Neoplasms 6Breast Neoplasms, Male 6Testicular Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lymphoma, B-Cell, Marginal Zone 5Febrile Neutropenia 5Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 5

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × pegfilgrastim × Clear all
NCT01840566 2026-05-28

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT02983097 2018-01-19

R²-DHAP

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 1/2 Terminated
34 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡